Lieven Annemans1, Jean-Pierre Van Buyten2, Thomas Smith3, Adnan Al-Kaisy3. 1. Department of Public Health, Ghent University, Ghent, Belgium. 2. Multidisciplinary Pain Centre, AZ Nikolaas, St. Niklaas, Belgium. 3. The Pain Management and Neuromodulation Centre, Guy's and St. Thomas' Hospital, London, United Kingdom.
Abstract
OBJECTIVES: Spinal cord stimulation (SCS) is an effective method of relieving chronic intractable pain, and one of its key indications is failed back surgery syndrome (FBSS). The objective of the current study was to evaluate the cost effectiveness of 10 kHz high-frequency SCS (HF10 SCS) compared to conventional medical management (CMM), reoperation, and traditional nonrechargeable (TNR-SCS) and rechargeable SCS (TR-SCS). METHODS: A health economic model of SCS in the United Kingdom was reproduced in the perspective of the health care system to simulate costs and quality adjusted life years (QALYs) over 15 years. In the model, both a decision tree and the Markov model were used to describe the health outcomes of the evaluated therapies. RESULTS: HF10 SCS therapy showed a favorable incremental cost-effectiveness ratio (ICER) of £3,153 per QALY gained as compared to CMM and established dominance (less costly, more QALYs) compared to TNR-SCS (£8,802 per QALY vs. CMM) and TR-SCS (£5,101 per QALY vs. CMM). CONCLUSION: This first analysis of the cost effectiveness of HF10 SCS suggests that it is more cost effective and provides a greater number of QALYs than both TNR-SCS and TR-SCS.
OBJECTIVES: Spinal cord stimulation (SCS) is an effective method of relieving chronic intractable pain, and one of its key indications is failed back surgery syndrome (FBSS). The objective of the current study was to evaluate the cost effectiveness of 10 kHz high-frequency SCS (HF10 SCS) compared to conventional medical management (CMM), reoperation, and traditional nonrechargeable (TNR-SCS) and rechargeable SCS (TR-SCS). METHODS: A health economic model of SCS in the United Kingdom was reproduced in the perspective of the health care system to simulate costs and quality adjusted life years (QALYs) over 15 years. In the model, both a decision tree and the Markov model were used to describe the health outcomes of the evaluated therapies. RESULTS:HF10 SCS therapy showed a favorable incremental cost-effectiveness ratio (ICER) of £3,153 per QALY gained as compared to CMM and established dominance (less costly, more QALYs) compared to TNR-SCS (£8,802 per QALY vs. CMM) and TR-SCS (£5,101 per QALY vs. CMM). CONCLUSION: This first analysis of the cost effectiveness of HF10 SCS suggests that it is more cost effective and provides a greater number of QALYs than both TNR-SCS and TR-SCS.
Authors: Neil E O'Connell; Michael C Ferraro; William Gibson; Andrew Sc Rice; Lene Vase; Doug Coyle; Christopher Eccleston Journal: Cochrane Database Syst Rev Date: 2021-12-02
Authors: Leonardo Kapural; Cong Yu; Matthew W Doust; Bradford E Gliner; Ricardo Vallejo; B Todd Sitzman; Kasra Amirdelfan; Donna M Morgan; Thomas L Yearwood; Richard Bundschu; Thomas Yang; Ramsin Benyamin; Abram H Burgher Journal: Neurosurgery Date: 2016-11 Impact factor: 4.654
Authors: David J DiBenedetto; Kelly M Wawrzyniak; Michael E Schatman; Ronald J Kulich; Matthew Finkelman Journal: J Pain Res Date: 2018-11-20 Impact factor: 3.133
Authors: Adnan Kasapovic; Yorck Rommelspacher; Martin Gathen; Davide Cucchi; Rahel Bornemann; Robert Pflugmacher; Sebastian G Walter Journal: Arthrosc Tech Date: 2019-09-19